SG11202100344WA - Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage - Google Patents
Methods and systems for adjusting tumor mutational burden by tumor fraction and coverageInfo
- Publication number
- SG11202100344WA SG11202100344WA SG11202100344WA SG11202100344WA SG11202100344WA SG 11202100344W A SG11202100344W A SG 11202100344WA SG 11202100344W A SG11202100344W A SG 11202100344WA SG 11202100344W A SG11202100344W A SG 11202100344WA SG 11202100344W A SG11202100344W A SG 11202100344WA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor
- coverage
- systems
- methods
- adjusting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702280P | 2018-07-23 | 2018-07-23 | |
| US201862741770P | 2018-10-05 | 2018-10-05 | |
| US201862782894P | 2018-12-20 | 2018-12-20 | |
| US201962824246P | 2019-03-26 | 2019-03-26 | |
| PCT/US2019/042882 WO2020023420A2 (en) | 2018-07-23 | 2019-07-22 | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100344WA true SG11202100344WA (en) | 2021-02-25 |
Family
ID=67659956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100344WA SG11202100344WA (en) | 2018-07-23 | 2019-07-22 | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11118234B2 (en) |
| EP (1) | EP3827100A2 (en) |
| JP (2) | JP7466519B2 (en) |
| KR (1) | KR20210038577A (en) |
| CN (1) | CN112752854A (en) |
| AU (1) | AU2019310041A1 (en) |
| CA (1) | CA3107983A1 (en) |
| SG (1) | SG11202100344WA (en) |
| WO (1) | WO2020023420A2 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| WO2016183106A1 (en) | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
| US20200258601A1 (en) * | 2018-10-17 | 2020-08-13 | Tempus Labs | Targeted-panel tumor mutational burden calculation systems and methods |
| US11640859B2 (en) | 2018-10-17 | 2023-05-02 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| JP2022519045A (en) * | 2019-01-31 | 2022-03-18 | ガーダント ヘルス， インコーポレイテッド | Compositions and Methods for Isolating Cell-Free DNA |
| CA3149504A1 (en) | 2019-08-22 | 2021-02-25 | Tempus Labs, Inc. | Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data |
| GB202003669D0 (en) * | 2020-03-13 | 2020-04-29 | Univ Oxford Innovation Ltd | Method for identifying neo-antigens |
| WO2021194837A1 (en) * | 2020-03-26 | 2021-09-30 | Memorial Sloan Kettering Cancer Center | Systems and methods for distinguishing pathological mutations from clonal hematopoietic mutations in plasma cell-free dna by fragment size analysis |
| CN111402952A (en) * | 2020-03-27 | 2020-07-10 | 深圳裕策生物科技有限公司 | Method and system for detecting tumor heterogeneity degree |
| US20210407623A1 (en) * | 2020-03-31 | 2021-12-30 | Guardant Health, Inc. | Determining tumor fraction for a sample based on methyl binding domain calibration data |
| CN112116956B (en) * | 2020-09-29 | 2024-04-19 | 深圳裕策生物科技有限公司 | Tumor single sample TMB detection method and device based on second-generation sequencing |
| CN115497556A (en) * | 2021-06-18 | 2022-12-20 | 广州燃石医学检验所有限公司 | Method for distinguishing somatic mutation from germline mutation |
| WO2022271730A1 (en) * | 2021-06-21 | 2022-12-29 | Guardant Health, Inc. | Methods and compositions for copy-number informed tissue-of-origin analysis |
| WO2022271159A1 (en) * | 2021-06-22 | 2022-12-29 | Foundation Medicine, Inc. | Systems and methods for evaluating tumor fraction |
| WO2023023402A2 (en) * | 2021-08-20 | 2023-02-23 | Guardant Health, Inc. | Methods for simultaneous molecular and sample barcoding |
| WO2023081889A1 (en) * | 2021-11-05 | 2023-05-11 | The Johns Hopkins University | Methods for treatment of cancer |
| WO2023086951A1 (en) * | 2021-11-12 | 2023-05-19 | Foundation Medicine, Inc. | Circulating tumor dna fraction and uses thereof |
| WO2023133131A1 (en) * | 2022-01-04 | 2023-07-13 | Natera, Inc. | Methods for cancer detection and monitoring |
| WO2023150633A2 (en) | 2022-02-02 | 2023-08-10 | Guardant Health, Inc. | Multifunctional primers for paired sequencing reads |
| CN114596918B (en) * | 2022-03-11 | 2023-03-24 | 苏州吉因加生物医学工程有限公司 | Method and device for detecting mutation |
| CN115404275B (en) * | 2022-08-17 | 2023-07-11 | 中山大学·深圳 | Method for evaluating tumor purity based on nanopore sequencing technology |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US20030017081A1 (en) | 1994-02-10 | 2003-01-23 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| DE69528706T2 (en) | 1994-08-19 | 2003-06-12 | Pe Corp Ny Foster City | COUPLED AMPFLICATION AND LIGATION PROCEDURE |
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| US6969488B2 (en) | 1998-05-22 | 2005-11-29 | Solexa, Inc. | System and apparatus for sequential processing of analytes |
| AR021833A1 (en) | 1998-09-30 | 2002-08-07 | Applied Research Systems | METHODS OF AMPLIFICATION AND SEQUENCING OF NUCLEIC ACID |
| US7501245B2 (en) | 1999-06-28 | 2009-03-10 | Helicos Biosciences Corp. | Methods and apparatuses for analyzing polynucleotide sequences |
| US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
| EP1218543A2 (en) | 1999-09-29 | 2002-07-03 | Solexa Ltd. | Polynucleotide sequencing |
| US20010043914A1 (en) | 1999-12-28 | 2001-11-22 | Edith Mathiowitz | Methods and products for tumor immunotherapy |
| US20030219765A1 (en) * | 2000-03-23 | 2003-11-27 | Jose Costa | Methods for evaluating cancer risk |
| WO2002004680A2 (en) | 2000-07-07 | 2002-01-17 | Visigen Biotechnologies, Inc. | Real-time sequence determination |
| DE60234464D1 (en) | 2001-11-28 | 2009-12-31 | Applied Biosystems Llc | Compositions and methods for selective nucleic acid isolation |
| US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
| WO2005108621A1 (en) * | 2004-04-30 | 2005-11-17 | Yale University | Methods and compositions for cancer diagnosis |
| US7170050B2 (en) | 2004-09-17 | 2007-01-30 | Pacific Biosciences Of California, Inc. | Apparatus and methods for optical analysis of molecules |
| JP2008513782A (en) | 2004-09-17 | 2008-05-01 | パシフィック バイオサイエンシーズ オブ カリフォルニア， インコーポレイテッド | Apparatus and method for molecular analysis |
| US7482120B2 (en) | 2005-01-28 | 2009-01-27 | Helicos Biosciences Corporation | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
| US7282337B1 (en) | 2006-04-14 | 2007-10-16 | Helicos Biosciences Corporation | Methods for increasing accuracy of nucleic acid sequencing |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| KR20230141927A (en) | 2010-12-30 | 2023-10-10 | 파운데이션 메디신 인코포레이티드 | Optimization of multigene analysis of tumor samples |
| US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| IL269097B2 (en) | 2012-09-04 | 2024-01-01 | Guardant Health Inc | Systems and methods to detect rare mutations and copy number variation |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US9805407B2 (en) | 2013-01-25 | 2017-10-31 | Illumina, Inc. | Methods and systems for using a cloud computing environment to configure and sell a biological sample preparation cartridge and share related data |
| CN105518151B (en) | 2013-03-15 | 2021-05-25 | 莱兰斯坦福初级大学评议会 | Identification and use of circulating nucleic acid tumor markers |
| PL2981921T3 (en) | 2013-04-03 | 2023-05-08 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP2994847A4 (en) | 2013-05-10 | 2017-04-19 | Foundation Medicine, Inc. | Analysis of genetic variants |
| CA2921620C (en) | 2013-08-19 | 2021-01-19 | Abbott Molecular Inc. | Next-generation sequencing libraries |
| SG10201805674YA (en) | 2014-01-02 | 2018-08-30 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| US20150292033A1 (en) | 2014-04-10 | 2015-10-15 | Dana-Farber Cancer Institute, Inc. | Method of determining cancer prognosis |
| US11085084B2 (en) * | 2014-09-12 | 2021-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and use of circulating nucleic acids |
| CN113694193A (en) | 2014-11-13 | 2021-11-26 | 约翰·霍普金斯大学 | Checkpoint blockade and microsatellite instability |
| MA40737A (en) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY |
| EP3240911B1 (en) * | 2014-12-31 | 2020-08-26 | Guardant Health, Inc. | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results |
| PT3256605T (en) * | 2015-02-10 | 2022-03-17 | Univ Hong Kong Chinese | Detecting mutations for cancer screening and fetal analysis |
| WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| US10364468B2 (en) | 2016-01-13 | 2019-07-30 | Seven Bridges Genomics Inc. | Systems and methods for analyzing circulating tumor DNA |
| CN114959918A (en) * | 2016-02-29 | 2022-08-30 | 基础医疗股份有限公司 | Methods and systems for assessing tumor mutational burden |
| CN109476731A (en) | 2016-02-29 | 2019-03-15 | 基础医药有限公司 | The method for the treatment of cancer |
| AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| TWI755395B (en) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | Combination of anti-pd-1 antibodies and radiation to treat cancer |
| US10711312B2 (en) * | 2016-07-12 | 2020-07-14 | The Regents Of The University Of California | Methods for immunotherapy-based treatment and assessment of cancer |
| US10294518B2 (en) | 2016-09-16 | 2019-05-21 | Fluxion Biosciences, Inc. | Methods and systems for ultra-sensitive detection of genomic alterations |
| TWI775781B (en) * | 2016-10-06 | 2022-09-01 | 美商建南德克公司 | Therapeutic and diagnostic methods for cancer |
| BR112019012958A2 (en) | 2016-12-22 | 2019-11-26 | Guardant Health Inc | methods and systems for nucleic acid molecule analysis |
| WO2018183817A2 (en) | 2017-03-31 | 2018-10-04 | Medimmune, Llc | Tumor burden as measured by cell free dna |
| WO2019018757A1 (en) | 2017-07-21 | 2019-01-24 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| CA3075932A1 (en) | 2017-09-20 | 2019-03-28 | Guardant Health, Inc. | Methods and systems for differentiating somatic and germline variants |
| CN111566225A (en) | 2017-11-03 | 2020-08-21 | 夸登特健康公司 | Normalization of tumor mutational burden |
| CA3083787A1 (en) | 2017-12-01 | 2019-06-06 | Personal Genome Diagnositics Inc. | Process for microsatellite instability detection |
| CN112088220B (en) | 2018-05-03 | 2024-04-19 | 豪夫迈·罗氏有限公司 | Surrogate markers and methods for tumor mutation load determination |
| EP3802878A1 (en) | 2018-06-04 | 2021-04-14 | Guardant Health, Inc. | Methods and systems for determining the cellular origin of cell-free nucleic acids |
| US20200258601A1 (en) | 2018-10-17 | 2020-08-13 | Tempus Labs | Targeted-panel tumor mutational burden calculation systems and methods |
-
2019
- 2019-07-22 CN CN201980062491.3A patent/CN112752854A/en active Pending
- 2019-07-22 CA CA3107983A patent/CA3107983A1/en active Pending
- 2019-07-22 JP JP2021503558A patent/JP7466519B2/en active Active
- 2019-07-22 AU AU2019310041A patent/AU2019310041A1/en active Pending
- 2019-07-22 KR KR1020217004814A patent/KR20210038577A/en unknown
- 2019-07-22 EP EP19753517.2A patent/EP3827100A2/en active Pending
- 2019-07-22 SG SG11202100344WA patent/SG11202100344WA/en unknown
- 2019-07-22 WO PCT/US2019/042882 patent/WO2020023420A2/en unknown
-
2020
- 2020-06-30 US US16/917,582 patent/US11118234B2/en active Active
-
2021
- 2021-07-28 US US17/387,830 patent/US20220098671A1/en active Pending
-
2024
- 2024-01-25 JP JP2024009403A patent/JP2024032860A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024032860A (en) | 2024-03-12 |
| JP7466519B2 (en) | 2024-04-12 |
| EP3827100A2 (en) | 2021-06-02 |
| AU2019310041A1 (en) | 2021-02-04 |
| US20220098671A1 (en) | 2022-03-31 |
| CN112752854A (en) | 2021-05-04 |
| CA3107983A1 (en) | 2020-01-30 |
| US11118234B2 (en) | 2021-09-14 |
| WO2020023420A2 (en) | 2020-01-30 |
| US20200370129A1 (en) | 2020-11-26 |
| KR20210038577A (en) | 2021-04-07 |
| WO2020023420A3 (en) | 2020-02-27 |
| JP2021531775A (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202100344WA (en) | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage | |
| EP4104175A4 (en) | Targeted-panel tumor mutational burden calculation systems and methods | |
| IL261126A (en) | Methods and systems for evaluating tumor mutational burden | |
| IL280350A (en) | Systems and methods for producing gene therapy formulations | |
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| EP3630286A4 (en) | Methods for real-time image guided radiation therapy | |
| IL282794A (en) | Therapeutic methods | |
| IL276808A (en) | Compositions and methods for cancer treatment | |
| EP3606962A4 (en) | Methods for treating cd73hi tumors | |
| IL288182A (en) | Systems and methods for evaluating tumor fraction | |
| EP3600549A4 (en) | Systems and methods for delivering radiotherapy | |
| IL287907A (en) | Methods for treating cancer | |
| EP3700617A4 (en) | Systems and methods for delivering neuroregenerative therapy | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| IL282093A (en) | Combination therapy for cancer | |
| EP3713576A4 (en) | Methods for cancer therapy | |
| SG11202106295WA (en) | Compositions and methods for cancer therapy | |
| EP3815744A4 (en) | Radiotherapy apparatus for animal | |
| GB2575637B (en) | Radiotherapy apparatus | |
| EP3894561A4 (en) | Methods for treating cancer | |
| GB201915586D0 (en) | System for radiation therapy | |
| EP3762098A4 (en) | Methods and systems for automatic radiotherapy treatment planning | |
| PT3905977T (en) | Systems and methods for tissue treatment | |
| GB2572337B (en) | Radiotherapy control system | |
| IL283577A (en) | Systems and methods for facilitating clone selection |